|Back to main|
Israeli therapeutics company Kamada sets terms for $60 million U.S. IPO
5/15/2013 11:51:00 PM
By: Renaissance Capital
Kamada, which is focused on orphan drugs and plasma-derived
protein therapeutics, announced terms for its IPO on Wednesday.
The Ness Ziona, Israel-based company plans to raise $60 million
by offering 5.6 million shares at a price of $10.75. At the
proposed price, Kamada would command a market value of $369
million. The company currently trades on the Tel Aviv Stock
Exchange under the ticker KMDA.